Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

Research into transcription factors deepen understanding of the 'language' of the genome, offering insights into human development.

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

New research has uncovered more about the complexity of human gene regulation by identifying certain sequences of proteins ...

ImmuneOnco retains a strong interest in CD47. A fusion protein and bispecific that hit the “don’t eat me” target remain part of the biotech’s plans. IMM47, the other program terminated by ...

The KISS bassist and co-lead singer is set to hit the road with The Gene Simmons Band in April and May Ilana Kaplan is a Staff Editor at PEOPLE. She has been working at PEOPLE since 2023.